<SEC-DOCUMENT>0001683168-22-004362.txt : 20220615
<SEC-HEADER>0001683168-22-004362.hdr.sgml : 20220615
<ACCEPTANCE-DATETIME>20220615084506
ACCESSION NUMBER:		0001683168-22-004362
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20220615
DATE AS OF CHANGE:		20220615

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PharmaCyte Biotech, Inc.
		CENTRAL INDEX KEY:			0001157075
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621772151
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40699
		FILM NUMBER:		221016685

	BUSINESS ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653
		BUSINESS PHONE:		(917) 595.2850

	MAIL ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVILEX, INC.
		DATE OF NAME CHANGE:	20090324

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EFOODSAFETY COM INC
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>pharmacyte_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Form 8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Current Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
<U>June 15, 2022</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B><U>PHARMACYTE
BIOTECH, INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Nevada</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-40699</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>62-1772151</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>3960 Howard Hughes Parkway, Suite 500<BR>
<U>Las Vegas, Nevada</U></B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>89169</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant's telephone number, including area code:
<B>(917) 595-2850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>N/A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
<FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Name of exchange on which registered</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, Par Value $0.0001 Per Share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">PMCB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this Chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt"><B>Item 8.01</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Other Events.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2022, PharmaCyte Biotech, Inc. (&ldquo;Company&rdquo;)
issued a press release, a copy of which is filed as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Important Additional Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, its directors and certain of its
executive officers are participants in the solicitation of proxies from the Company&rsquo;s shareholders in connection with the Company&rsquo;s
2022 Annual Meeting of Stockholders. The Company intends to file a definitive proxy statement and a WHITE proxy card with the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) in connection with any such solicitation of proxies from the Company&rsquo;s stockholders.
STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS
FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. The Company&rsquo;s
definitive proxy statement for the 2022 Annual Meeting of Stockholders contains information regarding the direct and indirect interests,
by security holdings or otherwise, of the Company&rsquo;s directors and executive officers in the Company&rsquo;s securities. Information
regarding subsequent changes to their holdings of the Company&rsquo;s securities can be found in the SEC filings on Forms 3, 4, and 5,
which are available on the Company&rsquo;s website at https://ir.pharmacyte.com/all-sec-filings or through the SEC&rsquo;s website at
www.sec.gov. Information can also be found in the Company&rsquo;s Annual Report on&nbsp;Form 10-K&nbsp;for the year ended April 30, 2022
on file with the SEC and in subsequent filings with the SEC. Updated information regarding the identity of potential participants, and
their direct or indirect interests, by security holdings or otherwise, will be set forth in the definitive proxy statement and other materials
to be filed with the SEC in connection with the 2022 Annual Meeting of Stockholders. Stockholders will be able to obtain the definitive
proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge
at the SEC&rsquo;s website at www.sec.gov. Copies will also be available at no charge at the Company&rsquo;s website at https://ir.pharmacyte.com/all-sec-filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 96px"><B>Item 9.01</B></TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt"><B> Financial Statements and Exhibits.</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">99.1 &nbsp;&nbsp;&nbsp;&nbsp;<A HREF="pharmacyte_ex9901.htm">Press Release, dated June 15, 2022, of PharmaCyte Biotech, Inc.</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: June 15, 2022</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>PHARMACYTE BIOTECH, INC.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 48%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ Kenneth L. Waggoner</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kenneth L. Waggoner</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and General Counsel</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pharmacyte_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 66px; width: 250px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PharmaCyte Biotech Issues Follow-Up Response
to Iroquois Capital&rsquo;s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LAS VEGAS, NV, June 15, 2022, PharmaCyte Biotech, Inc. (NASDAQ: PMCB)
(PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature
live-cell encapsulation technology, Cell-in-a-Box<SUP>&reg;</SUP>,&nbsp;today issued the following statement in response to the second
letter issued by Iroquois Capital (Iroquois) on June 9, 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We Take Issue with Iroquois&rsquo; Unfounded Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 7, 2022, we issued a detailed letter to our shareholders outlining
our growth strategy and additional steps being taken to enhance long-term shareholder value, and we have received positive responses from
many shareholders. We have always encouraged feedback from shareholders, which is how our relationship with Iroquois began. However, we
find Iroquois&rsquo; decision to continue to publicly issue unfounded statements that misrepresent our actions troubling and potentially
detrimental to long-term shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board and Management Refuse to be Distracted</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We remain focused on what matters most &ndash; the development of our
cellulose-based live-cell encapsulation technology, which we believe holds tremendous promise for treating various diseases that have
often been addressed unsuccessfully, including cancer, diabetes and malignant ascites.&nbsp;As we have stated, we are making substantial
progress toward a Phase 2b clinical trial for a promising therapy for pancreatic cancer.&nbsp;We have accelerated preparations for the
clinical trial for this therapy so that we will be ready to enroll our first patient and begin the clinical trial almost immediately upon
the FDA lifting the clinical hold. We believe this accelerated approach will save approximately six months or more of time from what was
originally estimated.&nbsp;We are confident that our previously stated strategy will deliver exponentially higher shareholder value over
time and that Iroquois&rsquo; persistence in raising issues that are already being addressed is an unnecessary distraction that does not
benefit shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Diverse Board Brings Extraordinary Experience in Our Target
Markets and We Are Actively Looking to Add Additional Capital Markets Experience</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We strongly disagree with Iroquois&rsquo; mischaracterization of our
Board as &ldquo;dysfunctional.&rdquo; To the contrary, our Board brings considerable relevant experience and has played a vital role in
helping to advance our operating strategy &ndash; working with management through the complexities associated with getting the FDA hold
lifted and preparing for the Phase 2b trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It has always been important, and remains critical, for our Board to
have a strong background and focus on the science that drives our leading product candidates. If the science fails, nothing else matters.
Most recently, we further strengthened the Board with our announcement in a press release dated April 5, 2022, of the addition of <FONT STYLE="background-color: #FEFEFE">Dr.
Matthias L&ouml;hr</FONT>, a person whose life&rsquo;s work and passion are specifically in the areas of the therapies PharmaCyte is developing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board, which Iroquois calls &ldquo;dysfunctional,&rdquo; oversaw
our successful uplisting to Nasdaq and two capital raises totaling almost $90 million. This large cash position has proven to be a critical
strategic advantage for a small cap research and development stage company like PharmaCyte, enabling us to remain focused on our longer-term
growth strategy in a very difficult financial environment. However, it is not lost on us that given the growth opportunities in front
of our company, that deeper and broader capital markets experience is now needed on our Board. We are in the process of reviewing and
thoroughly vetting candidates with that experience.&nbsp;What Iroquois failed to mention in its two letters is that we have, on multiple
occasions, offered to review candidates that Iroquois wishes to put forward. Iroquois has yet to recommend a single candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>New Executive Compensation Agreements Better Align Management with
Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Iroquois also insinuated that we are somehow being less than forthright
and engaging in poor corporate governance by not setting forth our entire executive compensation program in a Form 8-K. Consistent with
common practice, we will provide additional details as part of our Form 10-K for our fiscal year end which we plan to file in mid-July.
The new long-term Executive Compensation Agreements better align the compensation of our executive management with corporate performance
and include cash and equity bonuses tied to achievement of specified corporate goals. These goals are consistent with the strategy that
we have laid out and continue to reinforce with investors, including Iroquois.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conclusion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Well before Iroquois began publicly expressing its grievances, our
Board and management were planning many of the initiatives for which Iroquois is conveniently trying to take credit. We share in the frustration
with the current share price, and we are actively taking steps to address this as specified in our June 7 letter to our shareholders.
The most important thing we can do is continue to dedicate the majority of our time and resources to advancing through the clinic our
ground-breaking technology. We have heard and given thoughtful consideration and response to the opinions Iroquois has put forward. However,
we will not let one shareholder distract us from our ultimate mission &ndash; the continued development of and successful clinical trials
for our groundbreaking therapies &ndash; to the detriment of all other shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thank you for your continued support. We look forward to communicating
with you in the coming days on our progress in developing our leading product candidates.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With best wishes,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kenneth L. Waggoner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PharmaCyte Biotech</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PharmaCyte Biotech, Inc. is a biotechnology company developing cellular
therapies for cancer, diabetes and malignant ascites based upon a proprietary cellulose-based live-cell encapsulation technology known
as &ldquo;Cell-in-a-Box<SUP>&reg;</SUP>.&rdquo; This technology is being used as a platform upon which therapies for several types of
cancer, diabetes and malignant ascites are being developed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PharmaCyte&rsquo;s therapy for cancer involves encapsulating genetically
engineered human cells that convert an inactive chemotherapy drug into its active or &ldquo;cancer-killing&rdquo; form. For pancreatic
cancer, these encapsulated cells are implanted in the blood supply to the patient&rsquo;s tumor as close as possible to the site of the
tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the
normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide
flows through pores in the capsules, the live cells inside act as a &ldquo;bio-artificial liver&rdquo; and activate the chemotherapy drug
at the site of the cancer. This &ldquo;targeted chemotherapy&rdquo; has proven effective and safe to use in past clinical trials and we
believe results in little to no treatment related side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PharmaCyte&rsquo;s candidate therapy for Type 1 diabetes and insulin-dependent
Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release insulin in response
to the levels of blood sugar in the human body. The encapsulation of the cell line will be done using the Cell-in-a-Box<SUP>&reg;</SUP>
technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a &ldquo;bio-artificial
pancreas&rdquo; for purposes of insulin production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PharmaCyte&rsquo;s therapy for malignant ascites involves using the
same encapsulated cells PharmaCyte employs for pancreatic cancer but placing the encapsulated cells in the peritoneal cavity of a patient
and administering ifosfamide intravenously.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Safe Harbor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of PharmaCyte&rsquo;s
management and Board of Directors. Any statements contained in this press release which do not describe historical facts are forward-looking
statements subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from
those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to satisfactorily
address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included
in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking
statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except
as otherwise required by law, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">More information about PharmaCyte Biotech can be found at&nbsp;https://www.PharmaCyte.com.&nbsp;Information
may also be obtained by contacting PharmaCyte's Investor Relations Department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PharmaCyte Biotech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Telephone: 917.595.2856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email:&nbsp;<FONT STYLE="color: #0563C1"><U>InvestorRelations@PharmaCyte.c</U></FONT><U><FONT STYLE="color: #4F81BD">om</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Dr. Gerald W. Crabtree</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !, 2 # 2(  A$! Q$!_\0
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M.,C(&1G25"I%.36B,XXBE.2BGJ_E^9[91117.=(4444 %%%% !1110 4444
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M2L>+?MGW\GQO^-7PQ_9^TZ9C:7UVNN>)#$V"EI$&*H2.A*K*V#W,1[BO4?\
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CHO96[ZA&AB2[:)3*J'.5#XR!R>,]ZMT44.3>[!14;V6Y_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
